A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)

Inclusion criteria

• ✓. Males or females who are at least 18 years and no more than 80 years of age at Screening.
• ✓. Must have PN (defined as the presence of pruritic nodules due to chronic pruritus,) of more than 6 weeks duration despite treatment with current therapies such as antihistamines or corticosteroids ("treatment resistant" PN).
• ✓. Must have PN lesions on both arms, both legs, and/or the trunk (ie, the lesions must not be localized).
• ✓. Must have a VAS pruritus score of 70 or greater within 72 hours of Baseline.
• ✓. Males, non-fecund females (ie, surgically sterilized, if procedure was done 12 months before screening or subject is postmenopausal, without menses for 12 months before screening), or females of childbearing potential using an acceptable method of birth control for a period of 35 days before the first dosing, and all females must have a negative pregnancy test at the screening and baseline visits:
• ✓. Willing and able to understand and provide written informed consent.
• ✓. Willing and able to comply with study requirements and restrictions including the discontinuation of all current therapies for pruritus.
• ✓. Subjects must be in good health as determined by medical history, physical examination, and results of Electro Cardio Gram (ECG) and clinical laboratory tests (including urinalysis).